AstraZeneca Plc and the University of Oxford have become the third developers to report high levels of efficacy for their experimental vaccine to prevent Covid-19. Read in full with a subscriptionLearn more about subscribing to MedNous.Subscribe Clinical Research Company News Research & University News
